NewGenIvf Group Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered undervalued, ranking 69 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is low.Over the past month, multiple analysts have rated it as , with the highest price target at 225.00.In the medium term, the stock price is expected to trend down.
NewGenIvf Group Ltd's Score
Industry at a Glance
Industry Ranking
69 / 75
Overall Ranking
541 / 4521
Industry
Healthcare Providers & Services
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
NewGenIvf Group Ltd Highlights
StrengthsRisks
NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.43M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.53K shares, increasing 43.38% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
225.000
Target Price
+22400.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.